Previous 10 | Next 10 |
Data presented at the 2022 Annual Meeting of the American Association of Cancer Research New data from an open-label preclinical study in mice evaluating the changes in immune-related genes induced by multiple combinations of NBTXR3, anti-PD-1, anti-LAG-3, and anti-TIGIT...
Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and othe...
Nanobiotix S.A. (NBTX) Q4 2021 Earnings Conference Call March 31, 2022 08:00 AM ET Company Participants Kate McNeil - Senior Vice President, Investor Relations Laurent Levy - Co-Founder & Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Jonatha...
New data from Expansion Study 102 in high-risk, LA-HNSCC patients highlights potential clinical benefit of NBTXR3 showing a median Overall Survival reaching 23 months in evaluable patients; Data with minimum follow-up of one year for full study population anticipated in mid-2023 P...
Conference Call and Webcast to be Held at 8:00 A.M. EDT/2:00 P.M CET on March 31, 2022 NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) (Paris:NANO) (NASDAQ:NBTX) , a late-stage clinical biotechnology ...
Data published in Clinical and Translational Radiation Oncology Peer-reviewed clinical case study reported preliminary data on the first-in-human administration of NBTXR3 for the treatment of pancreatic cancer not eligible for surgery, demonstrating feasibility with ...
Data published in the International Journal of Nanobiotechnology Peer-reviewed preclinical data in an anti-PD-1 resistant lung cancer model show that adding NBTXR3 to a combination of radiotherapy, anti-PD-1, and anti-CTLA-4 produced significant antitumor effects...
Evaluation of NBTXR3 for global registration in priority head and neck cancer pathway proceeds with the first European patient randomized in global phase III NANORAY-312 study; US and Asia site activation expected in 2022 Priority NBTXR3 plus anti-PD-1 combination program po...
First patient randomized in pivotal phase III study evaluating radiotherapy-activated NBTXR3 with or without cetuximab in high-risk elderly patients with locally advanced head and neck squamous cell carcinoma The randomized study is designed to demonstrate treatment outcome ...
Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today a...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...